Clinical Trial Update: Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial exploring camrelizumab plus pyrotinib plus chemotherapy for HER2-positive advanced gastric or GEJ adenocarcinoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Neoplasms
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chemotherapy (chemotherapy)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fudan University | Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN